Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil

被引：0

作者：

Saggia, M. G. ^{[1
]}

Santos, E. A. ^{[1
]}

Nasciben, V ^{[1
]}

机构：

[1] Roche Brazil, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)70821-4

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A260 / A260

页数：1

共 50 条

[1] Cost minimization analysis of rituximab versus infliximab, adalimumab and etanercept for rheumatoid arthritis from a payer perspective in Brazil
Saggia, M. G.
Santos, E. A.
Nasciben, V
VALUE IN HEALTH, 2007, 10 (06) : A247 - A247
[2] COST ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT FOR RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF A PRIVATE PAY IN BRAZIL
Santos, E. A.
Saggia, M. G.
VALUE IN HEALTH, 2009, 12 (07) : A522 - A522
[3] ECONOMIC EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Fernandes, R. A.
Takemoto, M. L. S.
Tolentino, A. C. M.
Takemoto, M. M. S.
Santos, P. M. L.
Mould, J. F.
VALUE IN HEALTH, 2011, 14 (07) : A309 - A309
[4] Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
Gholami, Ahmad
Azizpoor, Jassem
Aflaki, Elham
Rezaee, Mehdi
Keshavarz, Khosro
BIOMED RESEARCH INTERNATIONAL, 2021, 2021
[5] A COST PER RESPONDER ANALYSIS OF ABATACEPT VERSUS ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AMONG PATIENTS WITH SHARED EPITOPE (SE) POSITIVITY FROM A UNITED STATES PAYER PERSPECTIVE
Park, S. H.
Han, X.
Lobo, F.
Nanji, S.
Patel, D.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1868 - 1869
[6] ETANERCEPT IN EARLY RHEUMATOID ARTHRITIS: ECONOMIC EVALUATION FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Takemoto, M.
Fernandes, R. A.
Fujii, R. K.
Mould, J.
Tang, B.
VALUE IN HEALTH, 2012, 15 (07) : A512 - A513
[7] Etanercept versus infliximab plus methotrexate in rheumatoid arthritis: A cost-effectiveness analysis from the Italian NHS perspective
Lopatriello, S
Berto, P
VALUE IN HEALTH, 2003, 6 (06) : 725 - 725
[8] Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients
Malone, DC
Ortmeier, BG
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 353 - 353
[9] BUDGET IMPACT ANALYSIS OF TO CILIZUMAB, INFLIXIMAB AND ETANERCEPT DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ECUADOR
Briceno, V
Naranjo, R.
Moscoso, J. D.
Salazar, D.
VALUE IN HEALTH, 2017, 20 (09) : A937 - A937
[10] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
Lawson, R. W.
Heatley, R. M.
Johnson, K., I
Khandker, R. K.
Singh, A.
VALUE IN HEALTH, 2010, 13 (07) : A308 - A308

← 1 2 3 4 5 →